New estimates of drug development costs
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
- Pindyck, Robert S, 1991.
"Irreversibility, Uncertainty, and Investment,"
Journal of Economic Literature, American Economic Association, vol. 29(3), pages 1110-1148, September.
- Pindyck, Robert, 1989. "Irreversibility, uncertainty, and investment," Policy Research Working Paper Series 294, The World Bank.
- Robert S. Pindyck, 1990. "Irreversibility, Uncertainty, and Investment," NBER Working Papers 3307, National Bureau of Economic Research, Inc.
- Pindyck, Robert S., 1990. "Irreversibility, uncertainty, and investment," Working papers 3137-90., Massachusetts Institute of Technology (MIT), Sloan School of Management.
- Wiggins, Steven N, 1981. "Product Quality Regulation and New Drug Introductions: Some New Evidence from the 1970s," The Review of Economics and Statistics, MIT Press, vol. 63(4), pages 615-619, November.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Ernst R. Berndt & Joseph P. Newhouse, 2010.
"Pricing and Reimbursement in U.S. Pharmaceutical Markets,"
NBER Working Papers
16297, National Bureau of Economic Research, Inc.
- Berndt, Ernst R. & Newhouse, Joseph P., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Working Paper Series rwp10-039, Harvard University, John F. Kennedy School of Government.
- Newhouse, Joseph Paul & Berndt, Ernst R., 2010. "Pricing and Reimbursement in U.S. Pharmaceutical Markets," Scholarly Articles 4450127, Harvard Kennedy School of Government.
- Chun-Hsien Wang & Jun-Yen Lee & Yi-Hua Chang, 2012. "Measuring productivity in the biotechnology industry using the global Malmquist index," Applied Economics Letters, Taylor & Francis Journals, vol. 19(9), pages 807-812, June.
- Ghazala Azmat & Marc Möller, 2012.
"The Distribution of Talent across Contests,"
Working Papers
600, Barcelona School of Economics.
- Ghazala Azmat & Marc Möller, 2018. "The Distribution of Talent Across Contests," SciencePo Working papers Main hal-03263984, HAL.
- Ghazala Azmat & Marc Möller, 2012. "The distribution of talent across contests," Economics Working Papers 1298, Department of Economics and Business, Universitat Pompeu Fabra, revised May 2013.
- Ghazala Azmat & Marc Möller, 2016. "The Distribution of Talent across Contests," Working Papers 789, Queen Mary University of London, School of Economics and Finance.
- Ghazala Azmat & Marc Möller, 2018. "The Distribution of Talent Across Contests," Post-Print hal-03263984, HAL.
- Ernst Berndt & Iain Cockburn & Karen Grépin, 2006. "The Impact of Incremental Innovation in Biopharmaceuticals," PharmacoEconomics, Springer, vol. 24(2), pages 69-86, December.
- Ghazala Azmat & Marc Möller, 2018.
"The Distribution of Talent Across Contests,"
Economic Journal, Royal Economic Society, vol. 128(609), pages 471-509, March.
- Ghazala Azmat & Marc Möller, 2012. "The Distribution of Talent across Contests," Working Papers 600, Barcelona School of Economics.
- Ghazala Azmat & Marc Möller, 2012. "The distribution of talent across contests," Economics Working Papers 1298, Department of Economics and Business, Universitat Pompeu Fabra, revised May 2013.
- Ghazala Azmat & Marc Möller, 2016. "The Distribution of Talent across Contests," Working Papers 789, Queen Mary University of London, School of Economics and Finance.
- Pedro Barros & Xavier Martinez-Giralt, 2008. "On international cost-sharing of pharmaceutical R&D," International Journal of Health Economics and Management, Springer, vol. 8(4), pages 301-312, December.
- Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
- Xu, Bixia, 2009. "R&D innovation and the value of cash in the biotech industry," Journal of Business Research, Elsevier, vol. 62(7), pages 750-755, July.
- Winghan Kwong & Edward Norton, 2007. "The Effect of Advertising on Pharmaceutical Innovation," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 31(3), pages 221-236, November.
- Bixia Xu, 2009. "Investment success and the value of investment opportunities: evidence from the biotech industry," Applied Financial Economics, Taylor & Francis Journals, vol. 19(7), pages 527-537.
- Pedro Pita Barros & Xavier Martínez-Giralt, 2006. "On insurance and the cost-sharing of pharmaceutical R&D," Working Papers 293, Barcelona School of Economics.
- Archibugi, Daniele & Bizzarri, Kim, 2004. "Committing to vaccine R&D: a global science policy priority," Research Policy, Elsevier, vol. 33(10), pages 1657-1671, December.
- Archibugi, Daniele & Bizzarri, Kim, 2004.
"Committing to vaccine R&D: a global science policy priority,"
Research Policy, Elsevier, vol. 33(10), pages 1657-1671, December.
- Archibugi, Daniele & .Kim Bizzarri, 2004. "Committing to Vaccine R&D: A Global Science Policy Priority/Comprometerse en la investigación y desarrollo de vacunas: una prioridad de la política científica global," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 22, pages 251-271, Agosto.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Toole, Andrew A., 2012. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," Research Policy, Elsevier, vol. 41(1), pages 1-12.
- Toole, Andrew A., 2011. "The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry," ZEW Discussion Papers 11-063, ZEW - Leibniz Centre for European Economic Research.
- Raymond J. March, 2021. "The FDA and the COVID‐19: A political economy perspective," Southern Economic Journal, John Wiley & Sons, vol. 87(4), pages 1210-1228, April.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Scherer, F. M., 2007. "Pharmaceutical Innovation," Working Paper Series rwp07-004, Harvard University, John F. Kennedy School of Government.
- Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
- Danzon, Patricia M. & Nicholson, Sean & Pereira, Nuno Sousa, 2005.
"Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances,"
Journal of Health Economics, Elsevier, vol. 24(2), pages 317-339, March.
- Patricia M. Danzon & Sean Nicholson & Nuno Sousa Pereira, 2003. "Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances," NBER Working Papers 9615, National Bureau of Economic Research, Inc.
- Simone Ghislandi & Michael Kuhn, 2016.
"Asymmetric information in the regulation of the access to markets,"
Department of Economics Working Papers
wuwp219, Vienna University of Economics and Business, Department of Economics.
- Ghislandi, Simone & Kuhn, Michael, 2016. "Asymmetric information in the regulation of the access to markets," Department of Economics Working Paper Series 219, WU Vienna University of Economics and Business.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
- Moshe Levy & Adi Rizansky, 2014. "Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 143-156, March.
- Frank Windmeijer & Eric de Laat & Rudy Douven & Esther Mot, 2006.
"Pharmaceutical promotion and GP prescription behaviour,"
Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 5-18, January.
- Eric de Laat & Rudy Douven & Esther Mot & F. Windmeijer, 2004. "Pharmaceutical promotion and GP prescription behaviour," CPB Discussion Paper 30, CPB Netherlands Bureau for Economic Policy Analysis.
- Dean Baker, 2007. "Stagnation in the Drug Development Process: Are Patents the Problem?," CEPR Reports and Issue Briefs 2007-07, Center for Economic and Policy Research (CEPR).
- Sedjo, Roger & Simpson, R. David, 1996. "Valuation of Biodiversity for Use in New Product Research in a Model of Sequential Search," RFF Working Paper Series dp-96-27, Resources for the Future.
- Sorisio, Enrico & Strøm, Steinar, 2006.
"Innovation and market dynamics in the EPO market,"
Memorandum
12/2006, Oslo University, Department of Economics.
- Sorisio, Enrico & Strøm, Steinar, 2009. "Innovation and market dynamics in the EPO market," HERO Online Working Paper Series 2006:3, University of Oslo, Health Economics Research Programme.
- Tannista Banerjee & Ralph Siebert, 2013.
"The Impact of R&D Cooperation on Drug Variety Offered on the Market: Evidence from the Pharmaceutical Industry,"
Auburn Economics Working Paper Series
auwp2013-20, Department of Economics, Auburn University.
- Tannista Banerjee & Ralph Siebert, 2014. "The Impact of R&D Cooperations on Drug Variety Offered on the Market. Evidence from the Pharmaceutical Industry," CESifo Working Paper Series 4567, CESifo.
- Tannistra Banerjee & Stephen Martin, 2015.
"Pharmaceutical Regulation and Innovative Performance: A Decision‐theoretic Model,"
Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 36(3), pages 177-190, April.
- Tannista Banerjee & Stephen Martin, 2013. "Pharmaceutical regulation and innovative performance: a decision-theoretic model," Auburn Economics Working Paper Series auwp2013-21, Department of Economics, Auburn University.
- Bardey, D. & Bommier, A. & Jullien, B., 2010.
"Retail price regulation and innovation: Reference pricing in the pharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 29(2), pages 303-316, March.
- Bardey, David & Bommier, Antoine & Jullien, Bruno, 2009. "Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 09-026, Toulouse School of Economics (TSE).
- Bardey, David & Bommier, Antoine & Jullien, Bruno, 2009. "Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry," IDEI Working Papers 432, Institut d'Économie Industrielle (IDEI), Toulouse.
- Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022.
"Bargaining and International Reference Pricing in the Pharmaceutical Industry,"
NBER Working Papers
30053, National Bureau of Economic Research, Inc.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," CEPR Discussion Papers 17293, C.E.P.R. Discussion Papers.
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," TSE Working Papers 22-1338, Toulouse School of Economics (TSE).
- Dubois, Pierre & Gandhi, Ashvin & Vasserman, Shoshana, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," Research Papers 3889, Stanford University, Graduate School of Business.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:jhecon:v:22:y:2003:i:2:p:325-330. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/inca/505560 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.